Priority Date: 24.07.12 (US 201261675013P)

ONCOLYTIC VIRUS THERAPY FOR RESISTANT TUMORS

  • Application ID: EP13822817
  • Status: EXAMINATION IN PROGRESS

Applicant

Attorney

operating since 1988
1007.41
Headquarter in London and 1 office
active in Legal Services, IP Consulting, Matchmaking and Trading, IP Portfolio Processing, IPR-related Financial Service, and IP-related Communication Service

Specialization

This patent has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING) Keltie LLP is specialized in the combination A61 and C12. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Sperling Fischer & Heyner, Zacco Denmark A/S, Lederer Keller Patentanwälte Partnerschaft mbB and 173 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 24.07.2012 - Priority Date (US 201261675013P)
  • 30.01.2014 - Publication A1 (WO2014018113)
  • 03.06.2015 - Publication A1 (EP2877572)